The following is a summary of “Aminoglycoside-modifying enzyme Eis2 represents a new potential in vivo target for reducing antimicrobial drug resistance in Mycobacterium abscessus complex” published in the December 2022 issue of Respiratory by Lorè et al.
Mycobacterium abscessus complex (MABSC) is a recently discovered opportunistic pathogen complex that is responsible for lung infections in individuals with pulmonary diseases such as bronchiectasis and cystic fibrosis after lung colonization. This complex was discovered in the United States. The MABSC complex is an opportunistic pathogen that was just recently found.
Because of the severity of the illness and the poor response to antibiotic treatment, it is quickly becoming one of the most clinically relevant nontuberculous mycobacteria. This is due to the fact that it is swiftly becoming one of the most clinically relevant nontuberculous mycobacteria. Because M.abscessus, M.bolletii, and M.massiliense are the three subspecies that are included in the MABSC , clinical relevance can be linked to the fact that these three subspecies are included in the MABSC. [C]linical relevance is attributed to the fact that [C]linical relevance is attributed to the fact.